JG
JSPR icon

Jefferies Group’s Jasper Therapeutics JSPR Stock Holding History

Jefferies Group’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,560
Closed -$340K – 1693
2020
Q1 		$340K Buy
+3,560
New +$348K ﹤0.01% 1482

Other funds holding JSPR

OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
SRCM
Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return
PMAM
Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.48% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
DCM
Dupont Capital Management Wilmington, Delaware $879M AUM 29.99% 1-Year Est. Return
AIMCA
Alberta Investment Management Corp (AIMCo) Edmonton, Alberta, Canada $16.7B AUM 23.27% 1-Year Est. Return

Jefferies Group's JSPR Position: Q2 2020 in Review

Jefferies Group sold out of Jasper Therapeutics (JSPR) in Q2 2020, closing a stake of 3,560 shares — an estimated $340K sold.

Jefferies Group first reported a position in JSPR in Q1 2020 and held it in 1 quarter. The position peaked at $340K in Q1 2020. 33 funds tracked by Wall St. Rank hold JSPR as of Q2 2020.

  • Jefferies Group reported no remaining Jasper Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Jefferies Group sold 3,560 Jasper Therapeutics shares in Q2 2020, an estimated $340K.
  • Jefferies Group first reported a position in Jasper Therapeutics in Q1 2020 and held it in 1 quarter.
  • Jefferies Group's Jasper Therapeutics position peaked at $340K in Q1 2020.
  • 33 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2020.

Based on Jefferies Group's 13F filing for Q2 2020, filed 14 Aug 2020.